Insulet (NASDAQ:PODD) Sets New 1-Year Low – Should You Sell?

Insulet Corporation (NASDAQ:PODD) reached a new 52-week low on Wednesday . The stock traded as low as $141.02 and last traded at $143.4140, with a volume of 177186 shares trading hands. The stock had previously closed at $153.80.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Oppenheimer dropped their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Raymond James Financial reduced their price target on shares of Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. Barclays decreased their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Wells Fargo & Company dropped their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $280.00 target price on shares of Insulet in a research note on Wednesday. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $252.48.

Insulet Trading Down 5.5%

The firm has a fifty day moving average of $188.59 and a 200 day moving average of $248.51. The firm has a market capitalization of $10.06 billion, a PE ratio of 33.86, a P/E/G ratio of 1.23 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet Corporation will post 6.43 EPS for the current year.

Institutional Investors Weigh In On Insulet

A number of large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its position in Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares during the last quarter. Cresset Asset Management LLC increased its position in shares of Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after acquiring an additional 177 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after acquiring an additional 7,030 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after acquiring an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in Insulet by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.